• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday

    6/3/24 10:39:44 AM ET
    $ADSK
    $AGIO
    $AMC
    $ARM
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADSK alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.

    Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. (NYSE:WM) for approximately $7.2 billion, including debt.

    Stericycle shares climbed 15% to $59.28 on Monday.

    Here are some other big stocks recording gains in today’s session.

    • GameStop Corp. (NYSE:GME) shares jumped 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock.
    • MarineMax, Inc. (NYSE:HZO) jumped 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax.
    • Liquidia Corporation (NASDAQ:LQDA) shares jumped 16.8% to $15.03 as the company said District Court issued favorable ruling and denied United Therapeutics’ request to block YUTREPIA™ launch.
    • Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) gained 15.5% to $11.18.
    • Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) gained 13.7% to $41.30 as the company reported Phase 3 results for mitapivat in reducing thalassemia transfusions.
    • Coherent Corp. (NASDAQ:COHR) rose 13.4% to $64.71 after the company announced the appointment of Jim Anderson as CEO.
    • CG Oncology, Inc. (NASDAQ:CGON) gained 11.8% to $36.34
    • Structure Therapeutics Inc. (NASDAQ:GPCR) gained 11.8% to $38.25 after the company reported 12-week results for obesity drug GSBR-1290, achieving significant weight loss.
    • Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose 11.8% to $23.9 after the company announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002..
    • AMC Entertainment Holdings, Inc. (NYSE:AMC) climbed 11.6% to $4.8330. The resumption of the meme rally came on the back of Keith Gill, also known as "Roaring Kitty," disclosing a substantial position in GameStop on the r/Superstonk Reddit forum.
    • Novavax, Inc. (NASDAQ:NVAX) rose 10.7% to $16.65.
    • Twist Bioscience Corporation (NASDAQ:TWST) gained 9.8% to $45.99.
    • Geron Corporation (NASDAQ:GERN) climbed 9.2% to $3.8750.
    • Telephone and Data Systems, Inc. (NYSE:TDS) climbed 9% to $21.67 as the company agreed to sell its wholly owned subsidiaries OneNeck IT Solutions and OneNeck Data Center to US Signal Company, LLC.
    • Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rose 8.9% to $24.99 as the company reported topline results from pivotal Phase 3 PALISADE study of investigational plozasiran.
    • Summit Therapeutics Inc (NASDAQ:SMMT) gained 8.8% to $9.45.
    • SkyWest, Inc. (NASDAQ:SKYW) jumped 8.4% to $80.97.
    • Autodesk, Inc. (NASDAQ:ADSK) rose 8.3% to $218.39 after the company issued preliminary results and said there will be no restatement or adjustment of any audited or unaudited financial statements.
    • Denali Therapeutics Inc. (NASDAQ:DNLI) jumped 8.1% to $20.06 as the company said that the FDA has selected DNL126 for participation in support for clinical trials advancing rare disease therapeutics pilot program.
    • Vera Therapeutics, Inc. (NASDAQ:VERA) gained 7.3% to $40.75.
    • Paramount Global (NASDAQ:PARA) rose 7.1% to $12.76 following reports suggesting Skydance is poised to announce the takeover of Paramount.
    • e.l.f. Beauty, Inc. (NYSE:ELF) gained 7% to $199.99. DA Davidson analyst Linda Bolton Weiser maintained e.l.f. Beauty with a Buy and maintained a $220 price target.
    • Arm Holdings plc (NASDAQ:ARM) rose 5% to $126.55 after the broader sector selloff on Friday when the U.S. government imposed sanctions on the Middle East regarding AI chips.

    Now Read This: $20M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

    Get the next $ADSK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADSK
    $AGIO
    $AMC
    $ARM

    CompanyDatePrice TargetRatingAnalyst
    e.l.f. Beauty Inc.
    $ELF
    4/3/2026$68.00In-line
    Evercore ISI
    e.l.f. Beauty Inc.
    $ELF
    4/2/2026$68.00In-line
    Evercore ISI
    Olema Pharmaceuticals Inc.
    $OLMA
    3/27/2026Peer Perform
    Wolfe Research
    Structure Therapeutics Inc.
    $GPCR
    3/26/2026Peer Perform
    Wolfe Research
    Arm Holdings plc
    $ARM
    3/26/2026$200.00Hold → Buy
    Needham
    Denali Therapeutics Inc.
    $DNLI
    3/26/2026$32.00 → $42.00Buy
    H.C. Wainwright
    Arm Holdings plc
    $ARM
    3/25/2026$166.00Mkt Perform → Outperform
    Raymond James
    Arm Holdings plc
    $ARM
    3/20/2026$205.00Reduce → Buy
    HSBC Securities
    More analyst ratings

    $ADSK
    $AGIO
    $AMC
    $ARM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on e.l.f. Beauty with a new price target

    Evercore ISI initiated coverage of e.l.f. Beauty with a rating of In-line and set a new price target of $68.00

    4/3/26 10:44:59 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Evercore ISI initiated coverage on e.l.f. Beauty with a new price target

    Evercore ISI initiated coverage of e.l.f. Beauty with a rating of In-line and set a new price target of $68.00

    4/2/26 8:09:51 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Wolfe Research initiated coverage on Olema Pharmaceuticals

    Wolfe Research initiated coverage of Olema Pharmaceuticals with a rating of Peer Perform

    3/27/26 8:52:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSK
    $AGIO
    $AMC
    $ARM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    $ADSK
    $AGIO
    $AMC
    $ARM
    SEC Filings

    View All

    Denali Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Denali Therapeutics Inc. (0001714899) (Filer)

    4/3/26 2:43:37 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by GameStop Corporation

    144 - GameStop Corp. (0001326380) (Subject)

    4/1/26 9:50:27 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.

    SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    4/1/26 5:32:23 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSK
    $AGIO
    $AMC
    $ARM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 67,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, o

    4/3/26 4:05:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

    Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026 SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. DNL593 is an investigational progranulin replacement therapy

    4/3/26 1:30:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance

    4/2/26 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSK
    $AGIO
    $AMC
    $ARM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Moore Daniel William

    4 - GameStop Corp. (0001326380) (Issuer)

    4/3/26 5:11:59 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    SEC Form 4 filed by Robinson Mark Haymond

    4 - GameStop Corp. (0001326380) (Issuer)

    4/3/26 5:10:46 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    SEC Form 4 filed by Starovasnik Melissa A.

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    4/3/26 4:00:10 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADSK
    $AGIO
    $AMC
    $ARM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farrell Matthew bought $464,814 worth of shares (5,000 units at $92.96), increasing direct ownership by 86% to 10,820 units (SEC Form 4)

    4 - e.l.f. Beauty, Inc. (0001600033) (Issuer)

    2/23/26 4:07:34 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ADSK
    $AGIO
    $AMC
    $ARM
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Geron Announces Appointment of New Members to its Board of Directors

    FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. "We are pleased to welcome Constantine and Pat to the Board, as they bring deep operational expertise cultivated over decades of biopharmaceutical industry leadership, particularly with commercial-stage organizations," said Elizabeth O'Farrell, Chair of the Board. "Their invaluable insights will be instrumental as we execute on our strategic priorities and drive commercial growth for RYTE

    3/26/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

    BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of

    3/25/26 7:30:00 AM ET
    $PCVX
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSK
    $AGIO
    $AMC
    $ARM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSK
    $AGIO
    $AMC
    $ARM
    Financials

    Live finance-specific insights

    View All

    SkyWest, Inc. Announces First Quarter 2026 Results Call Date

    SkyWest, Inc. (NASDAQ:SKYW) will host a live conference call and webcast after the market closes on Thursday, April 23, 2026 to discuss first quarter 2026 results. The format will include an overview of the quarterly results followed by a Q&A session. Thursday, April 23, 2026 2:30 p.m. Mountain Time Interested parties can access the webcast at: https://events.q4inc.com/attendee/179256265 The call-in number for US callers is 1-888-330-2455 The call-in number for international callers is 1-240-789-2717 The conference ID/Event Plus passcode is: 8322450 Please connect ten minutes before the scheduled hour to ensure a prompt starting time. If you have any questions, please contact Inve

    4/2/26 4:01:00 PM ET
    $SKYW
    Air Freight/Delivery Services
    Consumer Discretionary

    WM Sets Date for First Quarter 2026 Earnings Conference Call

    WM (NYSE:WM) announced that it will release first quarter financial results after the close of the market on Tuesday, April 28, 2026 and host its investor conference call Wednesday, April 29, 2026 at 10 a.m. ET. The live audio webcast of the earnings call will be accessible to the public by visiting investors.wm.com and selecting "Events & Presentations" from the website menu. A replay of the audio webcast will be available at the same location following the conclusion of the call. Participants who will be dialing in for the earnings call must register to obtain their dial in and passcode details. Participants may pre-register at any time, including up to and after the call start time.

    3/26/26 4:55:00 PM ET
    $WM
    Environmental Services
    Utilities

    Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

    First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin receptor to cross blood-brain barrierDenali's first medicine enabled by its TransportVehicle™ platform designed to deliver biotherapeutics to whole body, including brainRare Pediatric Disease Priority Review Voucher (PRV) awarded in connection with FDA approvalDenali to host conference call and webcast today at 12:30 p.m. Eastern time SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the U.S. Food and Drug Adm

    3/25/26 11:50:28 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care